The effect of strict rate control on B-type natriuretic peptide values and echocardiographic parameters in chronic

Yalçın Ozkurt, Ebru Ozpelit1, Ozgür Aslan

  • 1Dokuz Eylül University. ebru.ozpelit@gmail.com.

Kardiologia Polska
|May 22, 2014
PubMed

Insights

Strict rate control in patients with chronic atrial fibrillation (AF) significantly reduced B-type natriuretic peptide (BNP) levels and cardiac chamber volumes. This suggests a potential benefit for cardiovascular health in AF management.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Conflicting results exist regarding strict rate control's impact on cardiovascular outcomes in chronic atrial fibrillation (AF).
  • Current guidelines lack definitive evidence for strict rate control benefits, often confounded by medication side effects.
  • Assessing the pure effect of heart rate control on clinical endpoints in AF remains challenging.

Purpose of the Study:

  • To evaluate the effects of strict rate control on objective parameters in chronic AF patients.
  • Specifically assessed echocardiographic data and B-type natriuretic peptide (BNP) levels.
  • Investigated the impact of achieving a target resting heart rate (HR) below 80 bpm.

Main Methods:

  • 38 patients with chronic AF underwent assessment of echocardiographic parameters, BNP, and 24-hour Holter ECG.
  • Patients received therapy to achieve a target resting HR < 80 bpm.
  • Compared baseline and 3-month follow-up data, with subgroup analysis based on achieved HR control.

Main Results:

  • The strict rate control group (HR < 80 bpm) showed significant reductions in BNP, left ventricular volumes, and left/right atrial areas.
  • The non-strict rate control group maintained similar HR and exhibited increased BNP levels.
  • No significant changes in diastolic function (septal E/e') were observed in either group.

Conclusions:

  • Strict rate control in chronic AF patients led to significant decreases in BNP.
  • Achieving strict rate control resulted in a reduction in cardiac chamber volumes.
  • These findings suggest potential benefits of strict rate control beyond symptom management in AF.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.7K